Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 111051625 | 11105162 | 5 | F | 201411 | 20160815 | 20150511 | 20160818 | EXP | PHHY2011CA89391 | NOVARTIS | 82.88 | YR | M | Y | 0.00000 | 20160818 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 111051625 | 11105162 | 1 | PS | SANDOSTATIN | OCTREOTIDE ACETATE | 1 | Subcutaneous | 100 UG, ONCE/SINGLE (TEST DOSE) | 19667 | 100 | UG | 1X | |||||||
| 111051625 | 11105162 | 2 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 30 MG, EVERY 04 WEEKS (QMO) | U | 0 | 30 | MG | /month | ||||||
| 111051625 | 11105162 | 3 | SS | AFINITOR | EVEROLIMUS | 1 | Oral | 10 MG, QD | Y | 0 | 10 | MG | TABLET | QD | |||||
| 111051625 | 11105162 | 4 | SS | AFINITOR | EVEROLIMUS | 1 | Oral | 5 MG, QD | Y | 0 | 5 | MG | TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 111051625 | 11105162 | 1 | Neuroendocrine tumour |
| 111051625 | 11105162 | 2 | Neuroendocrine tumour |
| 111051625 | 11105162 | 3 | Neuroendocrine tumour |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 111051625 | 11105162 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 111051625 | 11105162 | Anorectal discomfort | |
| 111051625 | 11105162 | Blood pressure systolic increased | |
| 111051625 | 11105162 | Cataract | |
| 111051625 | 11105162 | Constipation | |
| 111051625 | 11105162 | Decreased appetite | |
| 111051625 | 11105162 | Dry mouth | |
| 111051625 | 11105162 | Fatigue | |
| 111051625 | 11105162 | Gingivitis | |
| 111051625 | 11105162 | Hepatic neoplasm | |
| 111051625 | 11105162 | Lethargy | |
| 111051625 | 11105162 | Malignant neoplasm progression | |
| 111051625 | 11105162 | Noninfective gingivitis | |
| 111051625 | 11105162 | Oral pain | |
| 111051625 | 11105162 | Pancreatic neoplasm | |
| 111051625 | 11105162 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 111051625 | 11105162 | 1 | 20101020 | 20101020 | 0 | |
| 111051625 | 11105162 | 2 | 20101029 | 0 | ||
| 111051625 | 11105162 | 3 | 20110328 | 20110610 | 0 | |
| 111051625 | 11105162 | 4 | 20141108 | 20150215 | 0 |